Pseudogene ANXA2P2 knockdown shows tumor-suppressive function by inhibition of the PI3K/PKB pathway in glioblastoma cells.
ANXA2P2
PI3K/PKB pathway
apoptosis
glioblastoma
invasion
viability
Journal
Journal of biochemical and molecular toxicology
ISSN: 1099-0461
Titre abrégé: J Biochem Mol Toxicol
Pays: United States
ID NLM: 9717231
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
04
02
2021
received:
31
05
2020
accepted:
18
05
2021
pubmed:
29
5
2021
medline:
2
9
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
The pseudogene annexin A2 pseudogene 2 (ANXA2P2) is highly expressed in glioblastoma (GBM). However, its role and mechanism involved in the progression of GBM remain poorly understood. ANXA2P2 messenger RNA expression was measured by quantitative reverse transcription-polymerase chain reaction. The protein levels were detected by Western blot. Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and lactate dehydrogenase (LDH) release assays. Cell invasive ability was investigated by the transwell assay and by epithelial-mesenchymal transition (EMT). Cell apoptosis was examined by flow cytometry. The results showed that ANXA2P2 expression was increased in GBM tissues and cells. Silencing of ANXA2P2 inhibited the activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB) pathway in GBM cells. Knockdown of ANXA2P2 decreased cell viability, promoted LDH release, suppressed cell invasive ability, and EMT, and induced cell apoptosis in GBM cells. The addition of the PI3K/PKB activator 740Y-P abrogated the effects of ANXA2P2 knockdown on cell viability, LDH release, invasive ability, and apoptosis. In conclusion, knockdown of ANXA2P2 inhibited cell viability and invasion but promoted the apoptotic rate by suppressing the PI3K/PKB pathway in GBM cells. ANXA2P2 may represent a new target for the treatment of GBM.
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22824Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
J. R. McFaline-Figueroa , E. Q. Lee , Am. J. Med. 2018, 131, 874.
A. S. Silantyev , L. Falzone , M. Libra , O. I. Gurina , K. S. Kardashova , T. K. Nikolouzakis , A. E. Nosyrev , C. W. Sutton , P. D. Mitsias , A. Tsatsakis , Cells 2019, 8, 863.
B. M. Alexander , T. F. Cloughesy , J. Clin. Oncol. 2017, 35, 2402.
G. Minniti , G. Lombardi , S. Paolini , Cancers 2019, 11, 336.
C. Velasquez , S. Mansouri , C. Mora , F. Nassiri , S. Suppiah , J. Martino , G. Zadeh , J. L. Fernandez-Luna , J. Oncol. 2019, 2019, 1740763.
C. Trejo-Solis , N. Serrano-Garcia , A. Escamilla-Ramirez , R. A. Castillo-Rodriguez , D. Jimenez-Farfan , G. Palencia , M. Calvillo , M. A. Alvarez-Lemus , A. Flores-Najera , A. Cruz-Salgado , J. Sotelo , Int. J. Mol. Sci. 2018, 19, 3773.
T. F. Kovalenko , L. I. Patrushev , Biochemistry (Moscow) 2018, 83, 1332.
X. Hu , L. Yang , Y. Y. Mo , Cancers 2018, 10, 256.
B. Liu , J. Liu , K. Liu , H. Huang , Y. Li , X. Hu , K. Wang , H. Cao , Q. Cheng , Biomed. Pharmacother. 2019, 117, 109116.
X. Zhao , S. Hao , M. Wang , D. Xing , C. Wang , Oncol. Lett. 2019, 17, 3511.
H. Xu , B. Chen , J. Xing , Z. Wei , C. Liu , Y. Qiu , Y. Lin , L. Ren , Oncol. Rep. 2019, 41, 3435.
Q. S. Wang , L. L. Shi , F. Sun , Y. F. Zhang , R. W. Chen , S. L. Yang , J. L. Hu , Dis. Markers 2019, 2019, 9267046.
S. Li , H. Zou , Y. Y. Shao , Y. Mei , Y. Cheng , D. L. Hu , Z. R. Tan , H. H. Zhou , Oncotarget 2017, 8, 106962.
I. A. Mayer , C. L. Arteaga , Annu. Rev. Med. 2016, 67, 11.
P. M. LoRusso , J. Clin. Oncol. 2016, 34, 3803.
X. Y. Zhou , H. Liu , Z. B. Ding , H. P. Xi , G. W. Wang , Genomics 2020, 112, 1021.
L. Miao , Z. Jiang , J. Wang , N. Yang , Q. Qi , W. Zhou , Z. Feng , W. Li , Q. Zhang , B. Huang , A. Chen , D. Zhang , P. Zhao , X. Li , Oncol. Rep. 2019, 42, 605.
A. N. Khachane , P. M. Harrison , BMC Genomics 2009, 10, 435.
E. S. Balakirev , F. J. Ayala , Annu. Rev. Genet. 2003, 37, 123.
S. Hirotsune , N. Yoshida , A. Chen , L. Garrett , F. Sugiyama , S. Takahashi , K. Yagami , A. Wynshaw-Boris , A. Yoshiki , Nature 2003, 423, 91.
Z. D. Zhang , Y. Li , Q. Fan , B. Zhao , B. Tan , X. F. Zhao , Neoplasma 2014, 61, 627.
S. A. Castaldo , T. Ajime , G. Serrão , F. Anastácio , J. T. Rosa , C. A. Giacomantonio , A. Howarth , R. Hill , P. A. Madureira , Cancers 2019, 11(4), 492.
C. Puch-Hau , I. A. Sanchez-Tapia , V. Patino-Suarez , M. A. Olvera-Novoa , M. Gullian Klanian , M. Quintanilla-Mena , O. Zapata-Perez , MethodsX 2019, 6, 1627.
K. J. Livak , T. D. Schmittgen , Methods 2001, 25, 402.
V. M. Crowley , K. Ayi , Z. Lu , K. T. Liby , M. Sporn , K. C. Kain , Malar. J. 2017, 16, 463.
L. Lossi , C. Castagna , A. Merighi , Int. J. Mol. Sci. 2018, 19, 3999.
S. Nagata , Annu. Rev. Immunol. 2018, 36, 489.
I. Manini , F. Caponnetto , A. Bartolini , T. Ius , L. Mariuzzi , C. Di Loreto , A. P. Beltrami , D. Cesselli , Int. J. Mol. Sci. 2018, 19, 147.
I. C. Iser , M. B. Pereira , G. Lenz , M. R. Wink , Med. Res. Rev. 2017, 37, 271.
M. Ehnman , W. Chaabane , F. Haglund , P. Tsagkozis , Curr. Oncol. Rep. 2019, 21, 90.
P. Du , Y. Liao , H. Zhao , J. Zhang , M.uyiti Keremu , K. Mu , Cell. Signal. 2020, 74, 109718.
M. Aoki , T. Fujishita , Curr. Top. Microbiol. Immunol. 2017, 407, 153.
H. F. Zhao , J. Wang , W. Shao , C. P. Wu , Z. P. Chen , S. T. To , W. P. Li , Mol. Cancer 2017, 16, 100.
H. Xin , N. Liu , X. Xu , J. Zhang , Y. Li , Y. Ma , G. Li , J. Liang , J. Cell. Biochem. 2019, 120, 15157.
H. Oppermann , H. Faust , U. Yamanishi , J. Meixensberger , F. Gaunitz , PLoS One 2019, 14, e0218972.
Y. Cheng , P. Xie , J. Biochem. Mol. Toxicol. 2019, 33, e22392.
S. H. Shahcheraghi , V. Tchokonte-Nana , M. Lotfi , M. Lotfi , A. Ghorbani , H. R. Sadeghnia , Curr. Pharm. Des. 2020, 26(15), 1729.
X.-J. Lu , A.-M. Gao , L.-J. Ji , X. Jiang , J. Med. Genet. 2015, 52, 17.
L. Poliseno , A. Marranci , P. P. Pandolfi , Front. Med. 2015, 2, 68.
M. Miyai , H. Tomita , A. Soeda , H. Yano , T. Iwama , A. Hara , J. Neurooncol. 2017, 135(3), 423.